Cancer Waiting Times Standards

Slides:



Advertisements
Similar presentations
Sarcoma cancer patient pathways Why do sarcoma cancer patients breach cancer waiting time targets?
Advertisements

CCG Assurance Framework Scorecard 2014/15 – Month 1 Sandra Iskander.
Breast cancer patient pathway
The Good, The Bad and The Patient Choice! Colorectal Patient Pathways Across the Network Presented by: Teresa Coombes Cancer, Oncology, Haematology and.
Gynaecology MDT Coordinator
NECN Colorectal NSSG Audit of Waiting Times for Lower GI Cancer Patients in NECN April 2010 – March 2011.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
New and Revised Definitions A Quick Summary Wait Times Measurement Toolkit.
Adult Social Care and Health Select Committee Cancer in Nottingham Julie O’Boyle Specialty Registrar Public Health NHS Nottingham City Dr Chris Packham.
Council of Governors Meeting Tim Bennett – Director of Finance and Steven Vaughan – Director of Operations &Performance July 2011.
Delays in the Diagnosis and Treatment of Oral Cancer Delays in the Diagnosis and Treatment of Oral Cancer M. A. Pogrel FDS, FRCS Professor and Chairman.
A two stage screening process – the pre-diabetes pathway.
Macmillan Ipswich Diagnostic Assessment Service (MIDAS)
Corporate Performance Report December 2012
WiFi name: WifiLoveMCR Password: internet Join the conversation on Twitter using #DrivingChange
2016/17 Q1 Performance Scorecard - DRAFT
2 November John Childs and Deborah Woodley
National Bowel Cancer Audit
Oesophago–Gastric Cancer
A Model for Breast Services in North Wales
HANA Audit Update for SSG
‘ACHIEVING WORLD CLASS CANCER OUTCOMES’
The 100,000 Genomes Project and the West of England Genomic Medicine Centre Brief update and overview provided by Catherine Carpenter-Clawson, Programme.
Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Oesophago–Gastric Cancer
Recognition and Referral of Suspected cancer NICE NG12 – 2Week Wait
Integrated Performance Report 26 October 2017
‘ACHIEVING WORLD CLASS CANCER OUTCOMES’
Dr James Carlton, Medical Adviser
The Emergency Medical Treatment and Active Labor Act
West of England Genomic Medicine Centre: Our Progress to Date
Pathway for patients with suspected Breast Cancer
Find and Treat All Missing Persons with TB
Achieving World-Class Cancer Outcomes A Strategy for England
Information and intelligence
Achieving World-Class Cancer Outcomes A Strategy for England
Finance Update.
Renal Transplantation at UHB
Pathway for patients with suspected Skin Cancer
User guide 62 day waiting time model
Pathway for patients with suspected Upper GI (OG) Cancer
National Cancer Diagnosis Audit
Proposal for Brain and CNS Presentation Audit Potential retrospective audit to understand the different routes into the neuro-onc service.
Achieving World-Class Cancer Outcomes A Strategy for England
Barts Health Trust 2WW Colorectal Workshop Dr Angela Wong,
Inquiry into geographical inequalities in breast cancer
Achieving World-Class Cancer Outcomes A Strategy for England
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Early Diagnosis Diagnostics Cancer Waits Survivorship South West Cancer Network 14 November 2014.
Integrated Performance Report End of Year V1.0
Trust Performance Update
CCG Assurance Framework Scorecard
Governing Body Quality Update
Pathway for patients with suspected colorectal cancer
Achieving World-Class Cancer Outcomes A Strategy for England
Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
Lung Cancer Pathway Dr Heather Harris - Consultant Radiologist
Audit Pharmacy Review Rosalyn D. Williams
Worcestershire Colorectal Cancer 2ww Pathway
Achieving World-Class Cancer Outcomes A Strategy for England
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Signing in for Patient Access
Upper GI SSG Meeting Statistics
Pathway for patients with suspected Breast Cancer
Breast Cancer SSG 14th November
28 Day Faster Diagnosis Standard
Airedale NHS Foundation Trust
Calderdale and Huddersfield NHS Foundation Trust
Somerset, Wiltshire, Avon & Gloucestershire Cancer Alliance
Presentation transcript:

Cancer Waiting Times Standards (A brief guide to the changes to cancer wait times)

Cancer Waiting Times Standards There are 8 Cancer Waiting Times Standards in total that the trust reports on monthly. TWW (referral to first seen) Breast Symptomatic TWW (referral to first seen) 62 Day (referral to first treatment) 31 Day (DTT to first treatment) 31 Day Subsequent Surgery (DTT to Treatment) 31 day Subsequent Drug Treatment (DTT to Treatment ) 62 Day Screening (referral to first treatment) 62 Day Upgrade (upgrade to treatment, monitored only) Fines for anything above tolerance other than 62 day

Recent and Future Changes? Breach Reallocation and Future 28 Diagnostic Target Why and the impact The current system is 15 years old and needed updating. Support direct to test models and earlier diagnosis. To make performance reporting fairer (for example in the past if a patient was referred to NBT after the 62 day target we would be unable to prevent the breach but we would still be help accountable for half a breach.) To develop timed pathways to ensure patients are treated in a timely manner To support the transfer of patients to specialist tertiary centres for investigation and treatment in a more timely manner

Inter-Provider Transfers The key days to remember are day 38 and day 24 All 2WW patients should be referred to the treating provider before day 38. All patients should be treated within 24 days of a referral being received (if the treatment date will fall outside of 62 days). If we receive a referral after day 38 we should still aim to treat by day 62 if we can.

How will breaches/treatments be reallocated

What if there is more than two providers?

What constitutes a full and correct IPT All paperwork received or patient signed over to UHB on the Cancer register. All staging complete (unless specified in an agreed pathway) Able to progress the patient. Referred for treatment and not MDT discussion only.

Current Cancer Performance

Any questions ?